How Sp1 and Sp3 Control Topoisomerase IIα in Breast Cancer Cells
Author Information
Author(s): Williams Amram O, Isaacs Richard J, Stowell Kathryn M
Primary Institution: Institute of Molecular Biosciences, Massey University
Hypothesis
The study investigates the functional relationship between Sp1 and Sp3 binding to the topoisomerase IIα promoter in vivo.
Conclusion
Sp3 acts as a dominant repressor over Sp1, leading to down-regulation of topoisomerase IIα in breast cancer cells treated with doxorubicin.
Supporting Evidence
- Sp1 and Sp3 bind to both GC1 and GC2 elements of the topoisomerase IIα promoter.
- Sp3 has a dominant repressive effect on Sp1-mediated activation.
- Changes in expression levels of Sp1 and Sp3 occur with exposure to doxorubicin.
Takeaway
This study shows that two proteins, Sp1 and Sp3, work together to control a gene important for cancer treatment, and when one is more active than the other, it can change how the gene works.
Methodology
The study used chromatin immunoprecipitation assays and transient cotransfection assays to analyze the binding of Sp1 and Sp3 to the topoisomerase IIα promoter in breast cancer cell lines.
Limitations
The exact molecular mechanisms behind the changes in expression of Sp1 and Sp3 remain uncertain.
Participant Demographics
Breast cancer cell lines (MDA MB 231) were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website